Primary brachial plexus tumors: imaging, surgical, and pathological findings in 25 patients

DEVIN K. BINDER, M.D., PH.D., JUSTIN S. SMITH, M.D., PH.D., AND NICHOLAS M. BARBARO, M.D.

Department of Neurological Surgery, University of California, San Francisco, California

Object. The authors report on the treatment of primary brachial plexus tumors in 25 patients at the University of California, San Francisco. They compare their findings with those obtained in similar series.

Methods. The authors reviewed the electronic and medical records, radiological images, operative reports, and pathological findings in 25 consecutive cases of primary brachial plexus tumors. Cases of metastatic lesions or adjacent neoplasms extending into and involving the brachial plexus were excluded.

At presentation patients ranged in age from 19 to 71 years (mean 47 ± 15 years), and neurofibromatosis was present in eight patients (32%). Presenting signs and symptoms included palpable mass (60%), numbness/paresthesias (44%), radiating pain (44%), local pain (16%), and weakness (12%). Duration of symptoms ranged from 2 months to 10 years. Neuroimaging revealed lesions ranging widely in size (volume ~1 to > 100 ml). Pathological diagnoses included schwannoma (15 [60%]), neurofibroma (five [20%]), malignant peripheral nerve sheath tumor (four [16%]), and desmoid tumor (one [4%]).

Conclusions. Primary tumors arising in the brachial plexus are rare. Careful workup, surgical technique, and attention to pathological diagnosis optimize management.

KEY WORDS • brachial plexus • schwannoma • neurofibroma • sarcoma • peripheral nerve tumor

Although many series of peripheral nerve tumors have been reported,1-7, 12, 14, 21, 28, 29, 31, 34, 35 few have been specifically and separately conducted to examine primary tumors of the brachial plexus. The authors of some larger series have reported peripheral nerve tumors in the head and neck but did not classify primary brachial plexus tumors separately. In a series involving 303 peripheral nerve tumors at Memorial Sloan–Kettering Cancer Center, 136 (45%) were located in the head and neck region.10 In 50 cases treated at the University of Illinois, 15 (30%) were located in the head and neck region.9 In an extensive review of 120 patients harboring MPNSTs treated at the Mayo Clinic during a 71-year period, Ducatman, et al.,14 indicated that 23 (19%) were located in the head and neck. Artico, et al.,1 reported 119 peripheral nerve sheath tumors, including 11 in the brachial plexus region.

The largest recent series of brachial plexus tumors was treated at LSUHSC.11, 20, 25, 29 In addition to providing a comprehensive review of the literature regarding brachial plexus tumors, Lusk, et al.,29 discussed the management of 57 brachial plexus tumors in 56 patients between 1968 and 1985. Of the 40 neural sheath–associated tumors, there were 26 neurofibromas, eight schwannomas, five MPNSTs, and one meningioma. The remaining 17 tumors included benign nonneural tumors (for example, desmoid and lipoma) and malignant nonneural tumors (breast cancer and lung cancer infiltration of the plexus).

In 2001, Ganju, et al.,20 reported on 111 brachial plexus tumors in 107 patients seen at LSUHSC between 1986 and 1998. In this later group, there were 36 schwannomas, 33 neurofibromas, 12 MPNSTs, 13 benign nonneural tumors, and 17 malignant nonneural tumors.

In this study, we reviewed the cases of primary nerve tumors arising in the brachial plexus at our institution during a 10-year period. We specifically excluded cases involving metastatic disease from our analysis in an attempt to examine the characteristics of primary brachial plexus tumors. Clinical presentation, neuroimaging, surgical, and pathological findings were reviewed.

CLINICAL MATERIAL AND METHODS

Patient Population

This study was conducted following an approved protocol from the Committee on Human Research at UCSF (approval no. H2338-24681-01). All patients presenting to UCSF with primary brachial plexus tumors between No-
Clinical, Neuroimaging, and Pathological Data

Available chart and electronic medical records were reviewed. Presenting signs and symptoms and relevant medical history were identified, with particular attention given to a history of NF, prior radiotherapy, or other tumors. Magnetic resonance imaging studies and reports were also reviewed to establish tumor size/volume, characteristics, and location.

Surgical Approach

Patients were positioned supine and general anesthesia was administered. In most cases, an anterior supraclavicular approach was used. Briefly, a curvilinear incision was made above the clavicle to conform to a skin crease. Sharp dissection was brought down through the skin and the platysma muscle. Depending on the site of the lesion (upper, middle, or lower trunk), the sternocleidomastoid muscle was detached from the clavicular head to facilitate exposure. In some cases, such as with inferior trunk lesions, infraclavicular exposure was required. The supraclavicular fat was dissected, and the omohyoid muscle was retracted. Careful attention was given to isolation and identification of all possible elements of the brachial plexus. Intraoperative stimulation and electromyography were conducted to define plexal anatomy and motor innervation. This allowed identification and sacrifice of nonfunctioning fascicles entering tumors. Once the tumor was identified grossly, the surgical microscope was brought into the field and used to assist in microdissection of the tumor and tumor capsule margins. Successive steps included dissection of adjacent plexus or nonnerve elements away from the tumor, identification and opening of the tumor capsule with concurrent intraoperative stimulation, and dissection of tumor away from adjacent nerve fascicles. In cases in which potentially significant motor impairment could result from sacrifice of nerve fascicles by gross-total removal of the tumor, a thin rind of tumor was left to preserve nerve continuity. Thus, the extent of tumor removal varied from extracapsular excision (gross-total resection), subcapsular gross-total resection, and sub-total resection.

Pathological Examination

In all cases, frozen-section specimens were sent for pathological evaluation. For the purposes of this report, we considered only the final pathological diagnosis. Detailed reports were examined to extract information about tumor size (in cm) and final pathological diagnosis.

RESULTS

Characteristics and Clinical Presentation

In our review we identified 25 patients with primary brachial plexus tumors. Neurofibromatosis was present in eight patients (32%). There was a trend toward younger age in those with NF (40 ± 19 years [mean ± SD]) compared with the patients without this diagnosis (51 ± 12 years) (p = 0.08).

Demographic and clinical characteristics are summarized in Table 1. Presenting signs and symptoms included the following: mass (60%), paresthesias/numbness (44%), radiating pain (44%), local pain (16%), and weakness (12%). The duration of symptoms ranged from 2 months to 10 years prior to treatment. In one case the lesion was discovered incidentally. Two patients (8%) had previously undergone EBRT, one for breast cancer and one for lymphoma.

Tumor Characteristics

The 25 tumors comprised a heterogeneous group of lesions, both in size and location (Table 2). The smallest-volume lesions were approximately 1 ml in volume and the largest were in excess of 100 ml. Tumors were found along the plexus at all points from the nerve roots and neural foramina through the distal plexus and proximal exiting nerves.

Intraoperative and Pathological Findings

Of 25 tumors, there were 15 schwannomas (60%) (Fig. 1A), five neurofibromas (20%) (Fig. 1B), four MPNSTs (16%) (Fig. 1C), and one desmoid tumor (4%) (Fig. 1D). All five neurofibromas and one of four MPNSTs were associated with a history of NF. Gross-total resection was achieved in all cases with schwannomas and in one of the five with neurofibromas. One intraoperative complication occurred: avulsion of an artery supplying the tumor from the right subclavian artery during tumor mobilization, but was successfully repaired without clinical sequelae.

DISCUSSION

Epidemiology and Presenting Symptoms

The mean age at diagnosis (47 years) in our series was higher than that in most series. The authors of a Mayo Clinic series of 120 MPNSTs reported a mean patient age of 35 years. In the most recent LSUHSC series, investigators reported a mean age of 25 years in cases involving neurofibromas associated with NF, 42 years in those with non-NF–associated neurofibromas, 42 years in those with schwannomas, and 44 years in cases involving MPNSTs. Interestingly, we observed a sex predilection, with 18 women and seven men in our series, which has been noted in some but not all other series. Of 120 patients in the Mayo series involving patients with MPNSTs, 52 were men and 68 were women. In the Memorial Sloan–Kettering series of 303 patients, 57% were women and 43% were men. In the recent LSUHSC series of 107 patients, however, 49% were men and 51% were women.

Patients with peripheral nerve tumors usually present with pain and paresthesias or with a palpable mass. In our series, the most common presenting symptoms were palpable mass, numbness/paresthesias, pain, and weakness, symptomatology in agreement with that in the LSUHSC series. Most often, early in the course, minimal neurological deficit will be present or there will be none at all. Manipulation of the mass can produce paresthesias or “shocks” in the distribution of the affected nerve, and this can be an important aid to diagnosis. Side-to-side greater than longitudinal mobility of the mass from the nerve is more common in cases of benign lesions,
Primary brachial plexus tumor

TABLE 1  
Demographic and clinical data at presentation in 25 patients with brachial plexus tumors

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Age (yrs), Sex</th>
<th>NF</th>
<th>Clinical Signs and Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>53, M</td>
<td>yes</td>
<td>lt supraclavicular mass for 10 yrs, recently enlarging; progressive local pain w/ radiation down forearm to hand for 1 yr</td>
</tr>
<tr>
<td>2</td>
<td>32, F</td>
<td>no</td>
<td>painless lt supraclavicular mass for 2 mos; manipulation of mass causes paresthesias/pain along ventral arm &amp; forearm &amp; third digit; decreased pinprick sensation in medial palm and ventral forearm</td>
</tr>
<tr>
<td>3</td>
<td>21, F</td>
<td>yes</td>
<td>painless lt supraclavicular mass; slight wasting of lt biceps; Grade 4+/5 lt biceps weakness</td>
</tr>
<tr>
<td>4</td>
<td>71, F</td>
<td>yes</td>
<td>2-yr history of rt supraclavicular nodule; resection 6 mos prior to current op; persistent rt posterior neck &amp; interscapular pain</td>
</tr>
<tr>
<td>5</td>
<td>69, F</td>
<td>no</td>
<td>1-yr history of lt neck mass; 1-mo history of lt hand paresthesias</td>
</tr>
<tr>
<td>6</td>
<td>49, M</td>
<td>no</td>
<td>1-yr history of painless enlarging rt supraclavicular mass</td>
</tr>
<tr>
<td>7</td>
<td>71, F</td>
<td>no</td>
<td>lt lat forearm-to-wrist paresthesias</td>
</tr>
<tr>
<td>8</td>
<td>50, M</td>
<td>no</td>
<td>painless enlarging rt supraclavicular mass</td>
</tr>
<tr>
<td>9</td>
<td>28, F</td>
<td>yes</td>
<td>2-yr history of rt arm pain radiating to 4th &amp; 5th fingers</td>
</tr>
<tr>
<td>10</td>
<td>52, F</td>
<td>no</td>
<td>history of metastatic breast cancer w/ prior EBRT presenting w/ enlarging lt supraclavicular mass</td>
</tr>
<tr>
<td>11</td>
<td>28, F</td>
<td>yes</td>
<td>progressive lt arm pain</td>
</tr>
<tr>
<td>12</td>
<td>43, F</td>
<td>no</td>
<td>10-yr history of pain &amp; numbness in lt hand; decreased grip strength</td>
</tr>
<tr>
<td>13</td>
<td>40, M</td>
<td>no</td>
<td>5-yr history of enlarging lt axillary mass; severe pain &amp; paresthesias in lt C7 distribution</td>
</tr>
<tr>
<td>14</td>
<td>47, F</td>
<td>no</td>
<td>lymphoma with prior EBRT 20 yrs age; 1-yr history of increasing rt arm pain</td>
</tr>
<tr>
<td>15</td>
<td>42, F</td>
<td>yes</td>
<td>lt arm &amp; shoulder pain, numbness, paresthesias</td>
</tr>
<tr>
<td>16</td>
<td>19, M</td>
<td>yes</td>
<td>enlarging lt supraclavicular mass &amp; lt arm paresthesias</td>
</tr>
<tr>
<td>17</td>
<td>52, F</td>
<td>no</td>
<td>5-yr history of enlarging lt supraclavicular mass w/ paresthesias in lt 2nd &amp; 3rd fingers w/ mild lt upper-extremity weakness</td>
</tr>
<tr>
<td>18</td>
<td>30, F</td>
<td>no</td>
<td>1-yr history of lt shoulder &amp; deltoid pain</td>
</tr>
<tr>
<td>19</td>
<td>53, M</td>
<td>no</td>
<td>3-yr history of intermittent severe rt neck pain radiating to rt thumb &amp; index finger</td>
</tr>
<tr>
<td>20</td>
<td>49, F</td>
<td>no</td>
<td>history of breast cancer w/ lt radical modified mastectomy w/out EBRT; 4-yr history of burning paresthesias along ulnar aspect of lt hand; symptoms induced by pressure on lt clavicle</td>
</tr>
<tr>
<td>21</td>
<td>47, F</td>
<td>yes</td>
<td>rt axillary mass associated w/ local pain</td>
</tr>
<tr>
<td>22</td>
<td>68, F</td>
<td>no</td>
<td>4-yr history of slowly enlarging lt supraclavicular mass; numbness of lt thumb &amp; index finger</td>
</tr>
<tr>
<td>23</td>
<td>52, F</td>
<td>no</td>
<td>10-yr history of enlarging rt neck mass; pain radiating down rt arm</td>
</tr>
<tr>
<td>24</td>
<td>40, M</td>
<td>no</td>
<td>4-yr history of rt index finger paresthesias; 1-yr history of rt hand cramping; symptoms triggered by shoulder movement or supraclavicular pressure</td>
</tr>
<tr>
<td>25</td>
<td>66, F</td>
<td>no</td>
<td>incidental lt brachial plexus mass identified during staging workup for breast cancer</td>
</tr>
</tbody>
</table>

whereas malignancy is associated with firmness and immobility.20,26

Radiological and Neuroimaging Findings

In cases of brachial plexus lesions, MR imaging is the study of choice to delineate the margins of the tumor from surrounding tissues with greatest contrast.22 Importantly, however, MR imaging is currently unable to differentiate between schwannoma and neurofibroma.5 Other imaging modalities may be useful in selected cases. Plain radiography can demonstrate apical pulmonary lesions potentially involving the brachial plexus. Computerized tomography scanning is optimal at revealing osseous erosion partially involving the brachial plexus. Computerized tomography scanning is optimal at revealing osseous erosion totally involving the brachial plexus. Computerized tomography scanning is optimal at revealing osseous erosion.22 Importantly, whereas malignancy is associated with firmness and immobility.20,26

Nonneoplastic lesions, especially hypertrophic neuropathy, may simulate neoplasms of the brachial plexus. Most commonly, interstitial hypertrophic neuropathy manifests as a sensorimotor polyneuropathy, and symptoms are usually bilateral with other associated neurological findings; however, several cases have been described in which patients presented with focal lesions including tumorlike infiltration of the brachial plexus.33 This condition may lead to thickening of peripheral nerves; evaluation of biopsy specimens demonstrates onion-bulb formation.33

Also termed neurogenic sarcoma and neurofibrosarcoma, MPNSTs are thought to be of neural origin.4,13 Other nonneural malignant tumors, such as soft-tissue sarcomas, can involve nerves by direct extension or metastasis. Although a small number of cases of MPNSTs have been reported in patients without NF,13 it has long been recognized that NF (especially NF Type 1, von Recklinghausen disease) is associated with a high incidence of MPNST. In our series, we observed a single desmoid tumor (Table 2, Case 8, Fig. 1D). Desmoid tumors are composed of infiltrative mesenchymal tissue, can encase and invade nerves and blood vessels, and are thus difficult to resect completely.6,26 Another nonneoplastic lesion that may rarely involve the brachial plexus is the neuromuscular hamartoma ("triton") tumor.2
Based on longer-term observation of a large series of patients, Brasfield and Das Gupta reported an overall incidence of 29%. In our series, one of four patients with MPNSTs also had NF.

Interestingly, three of our four patients with MPNSTs did not have NF; two of these patients had previously undergone radiotherapy, one for breast carcinoma and one for lymphoma. These lesions are probably best considered as postirradiation sarcomas. Indeed, the Mayo Clinic series of 120 consecutive MPNSTs included 13 cases of postirradiation sarcomas. In that study, the latency period (duration between radiotherapy and tumor diagnosis) was 17 years (range 5–29 years). Other authors have also reported the appearance of MPNSTs at sites previously irradiated. In addition, the fact that radiation can induce brachial plexopathy can potentially create a diagnostic dilemma. Other than two patients having undergone radiotherapy, there was nothing in the clinical presentation of these cases to aid in the prediction that a malignant tumor was present. In cases of NF, the presence of an enlarging mass or new pain may indicate the need for aggressive resection; however, several patients in this series presented with pain and/or an enlarging mass and harbored benign lesions. Thus, the presence of a new mass in the supraclavicular region should lead to recommendation for surgical exploration.

**Procedure-Related Complications**

Serious complications due to brachial plexus operations are infrequent. The primary risk is of neurological dysfunction caused by interruption of critical motor branches to arm and hand. In addition, however, plexus tumors can adhere to major vessels. In our series, there was one complication of vascular injury to the right subclavian artery during tumor mobilization (Case 6). Similarly, Ganju, et al., reported two cases of vascular injury during tumor removal.

**CONCLUSIONS**

We have reported the findings in 25 consecutive cases involving primary brachial plexus tumors (15 schwannomas, five neurofibromas, four MPNSTs, and one desmoid) seen at UCSF over a 10-year period. Clinical presentation most commonly included palpable mass, pain, numbness, or paresthesias. Gross-total removal was possible in all cases of schwannomas, whereas the other lesions
Primary brachial plexus tumor

were more difficult to resect completely. Final pathological diagnosis after examination of biopsy specimen or resection together with the clinical course can guide further therapy.

References

Fig. 1. Representative coronal T1-weighted Gd-enhanced fat-saturation MR images of four different primary brachial plexus tumors. A: Case 23. A cystic schwannoma. A 5.2 × 4.3 × 5-cm cystic mass within the subcutaneous tissues of the neck. A soft-tissue component of the mass extends toward the right C5–6 neural foramen. B: Case 9. A neurofibroma. A 5 × 6 × 4.8-cm enhancing lesion in the right axillary region. C: Case 15. An MPNST. A 5.2 × 3.2 × 2.9-cm heterogeneous mass arising from the C-6 nerve root with associated widening of the C5–6 left neural foramen. D: Case 8. A desmoid tumor. A 4.8 × 6.1 × 6.6-cm heterogeneous mass immediately posterior to proximal right clavicle.

D. K. Binder, J. S. Smith, and N. M. Barbaro


Manuscript received March 15, 2004. Accepted in final form April 2, 2004.
Address reprint requests to: Nicholas M. Barbaro, M.D., Department of Neurological Surgery, M779 Moffitt Hospital, Box 0112, University of California, San Francisco, San Francisco, California 94143-0112. email: barbaron@neurosurg.ucsf.edu.